Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 11

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 11
---
 ​ | ​ | ​   | ​ |  ​ | ​ | ​ | ​ | ​              | ​ |    ​ | ​ | ​ | ​ | ​                                                          | ​ |
| Frederick M. Hudson(2)(3)                    | ​ | ​ | ​   | ​ | 79 | ​ | ​ | ​ | ​              | ​ | 2010 | ​ | ​ | ​ | Director                                                   | ​ |
| Charles W. Newhall, III(3)(4)                | ​ | ​ | ​   | ​ | 80 | ​ | ​ | ​ | ​              | ​ | 2005 | ​ | ​ | ​ | Director                                                   | ​ |
| Class III Directors (Term maturing in 2027): | ​ | ​ | ​   | ​ |  ​ | ​ | ​ | ​ | ​              | ​ |    ​ | ​ | ​ | ​ | ​                                                          | ​ |
| Georges Gemayel, Ph.D.(1)(2)(3)(4)           | ​ | ​ | ​   | ​ | 64 | ​ | ​ | ​ | ​              | ​ | 2015 | ​ | ​ | ​ | Director                                                   | ​ |
| Bethany L. Sensenig(2)                       | ​ | ​ | ​   | ​ | 49 | ​ | ​ | ​ | ​              | ​ | 2023 | ​ | ​ | ​ | Director                                                   | ​ |

(1) Member of Science Committee (2) Member of Audit Committee (3) Member of Compensation Committee (4) Member of Governance and Nominating Committee Biographical Information The following is a brief biography of each nominee for election of director and a discussion of the specific experience, qualifications, attributes or skills that led the Board of Directors to select that director for nomination.

6

Class I Directors with Term of Office Expiring in 2025: Carrolee Barlow, M.D., Ph.D. , has served as a member of our Board of Directors since 2018. Dr. Barlow is a renowned expert in neuroscience and neurodegeneration, rare diseases and clinical development of new therapies. Dr. Barlow serves as Consulting Chief Medical Officer to several companies. Most recently, she was the Chief Medical Officer of Arialys, a position she held from August 2023 to March 2024. Prior to assuming that role, she served as Chief Medical Officer of EScape Bio, a position she held from January 2019 to August